Sign in or Register   Sign in or Register
  |  

Mouse Anti-C1S Recombinant Antibody (CBYY-C3034) (CBMAB-C4477-YY)

This product is mouse antibody that recognizes C1S. The antibody CBYY-C3034 can be used for immunoassay techniques such as: FC, IF, IHC-P, WB
See all C1S antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-C3034
Antibody Isotype
IgG2a
Application
FC, IF, IHC-P, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Immunoaffinity purified
Buffer
1 mg/mL
Preservative
50% glycerol, 1% BSA, PBS, pH 7.3
Concentration
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
complement C1s
Entrez Gene ID
UniProt ID
Alternative Names
Cytochrome B-245 Alpha Chain; Superoxide-Generating NADPH Oxidase Light Chain Subunit; Neutrophil Cytochrome B 22 KDa Polypeptide; Flavocytochrome B-558 Alpha Polypeptide; Cytochrome B-245, Alpha Polypeptide; Cytochrome B(558) Alpha Chain; Cytochrome B558 Subunit Alpha; P22 Phagocyte B-Cytochrome;
Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.
Biological Process
Complement activation Source: Reactome
Complement activation, classical pathway Source: Reactome
Innate immune response Source: UniProtKB-KW
Regulation of complement activation Source: Reactome
Cellular Location
Blood microparticle; Extracellular region; Extracellular space
Involvement in disease
Complement component C1s deficiency (C1SD): A rare defect resulting in C1 deficiency and impaired activation of the complement classical pathway. C1 deficiency generally leads to severe immune complex disease with features of systemic lupus erythematosus and glomerulonephritis.
Ehlers-Danlos syndrome, periodontal type, 2 (EDSPD2):A form of Ehlers-Danlos syndrome, a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDSPD2 is characterized by the association of typical features of Ehlers-Danlos syndrome with gingival recession and severe early-onset periodontal disease, leading to premature loss of permanent teeth. EDSPD2 transmission pattern is consistent with autosomal dominant inheritance.
PTM
The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.

Daugan, M., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., ... & Roumenina, L. (2021). Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of non-canonical functions of C1s. Cancer Immunology Research, canimm-0532.

Azasi, Y., Low, L. M., Just, A. N., Raghavan, S. S., Wang, C. W., Valenzuela-Leon, P., ... & Miller, L. H. (2021). Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence. Proceedings of the National Academy of Sciences, 118(22).

Gelbenegger, G., Schoergenhofer, C., Derhaschnig, U., Buchtele, N., Sillaber, C., Fillitz, M., ... & Jaeger, U. (2020). Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood advances, 4(6), 997-1005.

Riihilä, P., Viiklepp, K., Nissinen, L., Farshchian, M., Kallajoki, M., Kivisaari, A., ... & Kähäri, V. M. (2020). Tumour‐cell‐derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. British Journal of Dermatology, 182(3), 658-670.

Fouët, G., Gout, E., Wicker-Planquart, C., Bally, I., De Nardis, C., Dedieu, S., ... & Rossi, V. (2020). Complement C1q Interacts with LRP1 Clusters II and IV Through a Site Close but Different From the Binding Site of Its C1r and C1s-Associated Proteases. Frontiers in immunology, 11, 2706.

Jäger, U., D’Sa, S., Schörgenhofer, C., Bartko, J., Derhaschnig, U., Sillaber, C., ... & Jilma, B. (2019). Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood, The Journal of the American Society of Hematology, 133(9), 893-901.

Röth, A., Barcellini, W., D'Sa, S., Miyakawa, Y., Broome, C. M., Michel, M., ... & Berentsen, S. (2019). Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): results from the phase 3 cardinal study. Blood, 134, LBA-2.

Nikitin, P. A., Rose, E. L., Byun, T. S., Parry, G. C., & Panicker, S. (2019). C1s inhibition by BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro. The Journal of Immunology, 202(4), 1200-1209.

Almitairi, J. O., Girija, U. V., Furze, C. M., Simpson-Gray, X., Badakshi, F., Marshall, J. E., ... & Wallis, R. (2018). Structure of the C1r–C1s interaction of the C1 complex of complement activation. Proceedings of the National Academy of Sciences, 115(4), 768-773.

Chen, J. J., Schmucker, L. N., & Visco, D. P. (2018). Pharmaceutical machine learning: virtual high-throughput screens identifying promising and economical small molecule inhibitors of complement factor C1s. Biomolecules, 8(2), 24.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-C1S Recombinant Antibody (CBYY-C3034)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare